People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

The FDA expanded the indication for semaglutide (Wegovy) to treating adults with noncirrhotic metabolic ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

In patients with type 2 diabetes (T2D), treatment with oral semaglutide demonstrated a modest but significant reduction in ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Weight Loss RX Reviews today published their groundbreaking "2025 American Compounded Semaglutide Consumer Insight Report" – ...